PharmaShots Weekly Snapshots (April 04-08, 2022)
Published: Apr 8, 2022 | Tags: Aptinyx, NYX-2925, P-IIb Study, Painful, Diabetic Peripheral Neuropathy
Published: Apr 8, 2022 | Tags: VYNE, FMX114, P-Ib/IIa Trial, Atopic Dermatitis
Published: Apr 8, 2022 | Tags: Tonix, P-III, RESILIENT Study, TNX-102 SL, Fibromyalgia
Published: Apr 8, 2022 | Tags: Janssen, Xarelto, rivaroxaban, Aspirin, P-III, VOYAGER PAD Trial, PAD, Co-Morbid Conditions
Published: Apr 8, 2022 | Tags: Propella, Jiangsu Aosaikang, CGS-200-5, Pain Greater China
Published: Apr 8, 2022 | Tags: Jazz, Werewolf, WTX-613, PREDATOR, Protein, Engineering Technology
Published: Apr 7, 2022 | Tags: Pregene, CellPoint, PRG-1801, Hematological Indications
Pfizer to Acquire ReViral for ~$525M
Published: Apr 7, 2022 | Tags: Pfizer, Acquire, ReViral, ~$525M
Published: Apr 7, 2022 | Tags: Regeneron, Sanofi, Dupixent, dupilumab, EC, Approval, Children, Asthma, Type 2 Inflammation
Published: Apr 7, 2022 | Tags: BioXcel Therapeutics, Igalmi, dexmedetomidine, US, FDA, Approval, Agitation, Schizophrenia, Bipolar I or II Disorder
Published: Apr 7, 2022 | Tags: Novartis, Vijoice, alpelisib, US, FDA, Approval, PIK3CA, Overgrowth Spectrum
Published: Apr 7, 2022 | Tags: Harbour BioMed, Out-License, Agreement, AstraZeneca, HBM7022, Solid Tumors, HBICE Platform
Published: Apr 6, 2022 | Tags: Innovent, Pemazyre, pemigatinib, NMPA, Approval, Cholangiocarcinoma
Published: Apr 6, 2022 | Tags: Evozyne, Takeda, Gene Therapies, Rare Genetic Diseases, Protein Engineering Platform
Published: Apr 6, 2022 | Tags: ViGeneron, Regeneron, Gene Therapies, Inherited Retinal Disease
Published: Apr 6, 2022 | Tags: Theravance Biopharma, Ampreloxetine, P-III, Study 0170, Symptomatic Neurogenic Orthostatic Hypotension
Published: Apr 6, 2022 | Tags: Dialectic, DT2216, US FDA’s Fast Track Designation, Peripheral, Cutaneous, T-Cell Lymphoma
Published: Apr 6, 2022 | Tags: Allergan, Vuity, P-III, VIRGO Trial, Presbyopia, Age-Related, Blurry Near Vision
Published: Apr 5, 2022 | Tags: Imara, P-IIb, Ardent, Forte Trial, Tovinontrine, IMR-687, Sickle Cell Disease, Beta-Thalassemia
Published: Apr 5, 2022 | Tags: BMS, Opdivo, nivolumab, EC, Approval, Muscle-Invasive Urothelial Carcinoma
Published: Apr 5, 2022 | Tags: argenx, Vyvgart, efgartigimod alfa-fcab, P-III, ADAPT+ Trial, Generalized Myasthenia Gravis, AAN 2022
Published: Apr 5, 2022 | Tags: Abbott, Aveir VR Leadless, Pacemaker System, US, FDA, Approval, Slow Heart Rhythms
Published: Apr 5, 2022 | Tags: Protalix BioTherapeutics, Chiesi, PRX-102, P-III, BALANCE Trial, Fabry Disease
Published: Apr 5, 2022 | Tags: Immunocore, Kimmtrak, tebentafusp, EC, Approval, Unresectable, Metastatic, Uveal Melanoma
Published: Apr 4, 2022 | Tags: Junshi Biosciences, TAB009, JS009, US, FDA, Approval, Advanced Solid Tumors
Published: Apr 4, 2022 | Tags: BridgeBio Pharma, Acoramidis, AG10, P-II, OLE Study, Transthyretin Amyloid Cardiomyopathy, ACC, 2022
Published: Apr 4, 2022 | Tags: Sanofi, Regeneron, US, FDA, Acceptance, sBLA, Priority Review, Dupixent, dupilumab, Eosinophilic Esophagitis
Published: Apr 4, 2022 | Tags: Ionis, P-IIb, ETESIAN Study, ION449, Hypercholesterolemia, ACC 2022
Published: Apr 4, 2022 | Tags: Innovent, IBI306, P-III, CREDIT-2 Study, Heterozygous Familial Hypercholesterolemia, ACC 2022
Published: Apr 4, 2022 | Tags: BMS, Mavacamten, EXPLORER-LTE Cohort, MAVA-LTE Study, Symptomatic, Obstructive, Hypertrophic Cardiomyopathy
Related Post: PharmaShots Weekly Snapshots (March 28 – April 01, 2022)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com